Vicky Makker, MD, on Endometrial Cancer: Lenvatinib Plus Pembrolizumab
SGO 2021 Virtual Annual Meeting on Womens Cancer
Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overall response rate, compared with treatment of physician’s choice for advanced endometrial cancer. These results were achieved regardless of mismatch repair status following platinum-based chemotherapy (ID #10191).
The ASCO Post Staff
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin yielded promising clinical outcomes in chemotherapy-naive advanced or recurrent endometrioid cancer (ID # 10244).
The ASCO Post Staff
Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important treatment tool (ID# 10253).
The ASCO Post Staff
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.
The ASCO Post Staff
Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).
The ASCO Post Staff
Supriya Chopra, MD, of Tata Memorial Centre, discusses a final analysis of the phase III PARCER trial, which showed that image-guided intensity-modulated radiotherapy is superior to conventional radiotherapy in reducing bowel toxicity in women with cervical cancer. Acute diarrhea was also reduced, with no difference in disease-related outcomes (ID# 10224).
